F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice-Reference-Cited by-同舟云学术

F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice

Published:2007-04-24 Issue:4 Volume:375 Page:241-250
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmied Arch Pharmacol

Author:

Assié Marie-Bernadette,Bardin Laurent,Auclair Agnès,Consul-Denjean Nathalie,Sautel François,Depoortère Ronan,Newman-Tancredi Adrian

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00210-007-0162-x.pdf

Reference35 articles.

1. Abi-Dargham A, Laruelle M (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 20:15–27

2. Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63–101

3. Assié M-B, Bardin L, Auclair A, Consul-Denjean N, Sautel F, Kleven MS, Depoortère R, Newman-Tancredi A (2006a) F15063, a novel antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: III) Duration of brain D2-like receptor occupancy, antipsychotic-like activity and plasma concentration in rodents. Eur Neuropsychopharmacol 16(Suppl 4):S432

4. Assié M-B, Dominguez H, Consul-Denjean N, Newman-Tancredi A (2006b) In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn Schmiedebergs Arch Pharmacol 373:441–450

5. Bantick RA, Deakin JFW, Grasby PM (2001) The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15:37–46

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors;Journal of Alzheimer's Disease;2012-11-14

2. Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds;Neurobiology of Disease;2010-01

3. Differences among conventional, atypical and novel putative D2/5-HT1A antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys;Behavioural Brain Research;2009-11

4. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist and 5-HT1A receptor agonist properties: Influence on immediate-early gene expression in rat prefrontal cortex and striatum;European Journal of Pharmacology;2009-10

5. Nanowired-Drug Delivery Enhances Neuroprotective Efficacy of Compounds and Reduces Spinal Cord Edema Formation and Improves Functional Outcome Following Spinal Cord Injury in the Rat;Brain Edema XIV;2009-08-31